EuroHealthNet welcomes the Oslo Medicines Initiative and its aims to help to remedy the lack or inadequacy of effective “social contracts” and regulations establishing and ensuring clear rights and duties of all involved in medicines development processes. This is needed to ensure critical and innovative products are equitably available for people in need, and to apply lessons of the COVID-19 syndemic, particularly on effective cooperation between stakeholders at all levels of governance and supply.